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PRP21
THE ECONOMIC IMPACT OF HOMEOPATHIC
MANAGEMENT: THE FRENCH EXAMPLE 
Taïeb C, Myon E
Pierre Fabre SA, Boulogne Billancourt, France
OBJECTIVE: Homeopathy is based on the principle of
similitude, using at non-toxic doses, in a sick patient,
medicinal substances of mineral, plant or animal origin,
which, at toxic doses, are capable of triggering in healthy
individuals a range of symptoms similar to those observed
during the disease under consideration. Homeopathy is
mainly employed in cases of ENT disease, anxiety disor-
ders and sleep disorders. Today, in France, about 2 in
every 10 physicians prescribe frequently or regularly 
some sort of homeopathic-based treatment. METHOD:
hOMEO is a longitudinal, prospective, observational
programme. Three hundred patients with rhinitis chronic,
treated either by homeopathic (HM) or allopathic man-
agement (AM), will be followed during 6 months. In this
study, the level of resources used and patient satisfaction
will be collected in order to provide conﬁrmation of the
economic relevance of reliance on homeopathic manage-
ment versus allopathic management. RESULTS: At in-
clusion time, both groups expressed the same level of
symptoms. There are no differences neither in the number
nor in the type of symptoms due to their rhinitis chronic.
Three months later, the chronic rhinitis symptoms are
resorbed within the same proportion for both groups.
None symptoms have been better or badly resorbed the
one than the other. At 3 months, the SF-12 score on the
physical dimension are the following HM 51.8, AM 47.9
(p < 0.05), the inclusion score being comparable between
the two groups at inclusion induced that patients treated
by a homeopathic management improved their QoL on
this dimension. The quarterly cost of care for patients
treated with allopathic management (€45.74) is 30%
more expensive than the quarterly cost of care for patients
treated with homeopathic management (€27). This dif-
ference is essentially due to a higher frequency of consul-
tations and a more expensive mean medical prescription
with the allopathic management. CONCLUSION:
Reliance on homeopathic management appears to give
rise to an annual reimbursement cost, which is half that
induced by allopathic general practitioners.
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IS CISATRACURIUM COST EFFECTIVE FOR
NEUROMUSCULAR BLOCKADE IN THE ICU? A
MARKOV COMPUTER SIMULATION STUDY
Macario A1, Marx SE2, Chow JL1
1Stanford University, Stanford, CA, USA; 2Abbott Laboratories,
Lake Forest, IL, USA
OBJECTIVES: Care of patients with acute respiratory
distress syndrome (ARDS) is challenging and costly.
Administering muscle relaxants may facilitate mechanical
ventilation and improve oxygenation. After the relaxant
is discontinued, some patients have delayed recovery 
of neuromuscular function, while other patients develop
prolonged muscle weakness—acute quadriplegic myopa-
thy syndrome (MYOPATHY). The objective of this study
was to examine the incremental cost-effectiveness ratio
(ICER) of cisatracurium versus using a traditional steroid
based agent—vecuronium. METHODS: We designed a
Markov ICER computer model. The base case involved a
55-year-old man admitted to the ICU for ARDS and then
paralyzed for 3.5 days. Patients were modeled to be in
one of the following health states: ICU-intubated, ICU-
extubated, hospital ward, long-term care, home, or death.
Patient progression was divided into 3.5 day cycles over
six months. One trial found the average recovery after
cisatracurium to be one hour versus 6 hours with vecuro-
nium. Approximately 27% of ICU patients paralyzed 
for 3.5 days would be expected to develop MYOPATHY
within 7 days. However, it is not evident that
cisatracurium reduces this incidence. RESULTS: Our
modeling predicted the total cost for an ARDS patient to
be $58,629. At 6 months: mortality = 43%, patients dis-
charged home = 32%, in-hospital = 8%, and long term
care facility = 17%. Using average wholesale prices,
cisatracurium costs $599 for 3.5 days, versus $332 for
vecuronium. The modeling suggests that cisatracurium is
cost-effective (the ICER is < $35,000/QALY) if intubation
time is reduced by 7%, or if ICU extubated time is
reduced by 1.8%, or if the time the patient is in the ward
is reduced by 2.3%. CONCLUSIONS: Incremental costs
for cisatracurium are a very small portion of the total cost
of care for ARDS patients. If cisatracurium use leads to
very small reductions in ICU time, or ward length, it
becomes a cost-effective intervention.
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ECONOMIC OUTCOMES OF TREATING
CHRONIC OBSTRUCTIVE PULMONARY
DISEASE WITH INHALED CORTICOSTEROIDS
AND LONG-ACTING b-AGONISTS IN A HEALTH
MAINTENANCE ORGANIZATION
Gagnon YM1, Levy AR2, Hurley JS3, Frost FJ3, Spencer MD4,
Maple DW3, Briggs AH5
1Occam Research & Consulting,Vancouver, BC, Canada;
2University of British Columbia,Vancouver, BC, Canada;
3Lovelace Respiratory Research Institute, Albuquerque, NM,
USA; 4GlaxoSmithKline Global Health Outcomes, Uxbridge,
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OBJECTIVES: There is growing recognition of the public
health challenge posed by treating persons with chronic
obstructive pulmonary disease (COPD). Although treat-
ment options are limited, observational studies have
shown that long-acting beta agonists (LABA) and/or
inhaled corticosteroids (ICS) may prolong survival. We
investigated the cost-effectiveness of competing strategies
for treating COPD. METHODS: Subject-level cost and
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survival data were extracted from a sample of members
enrolled in a large Health Maintenance Organization.
Study subjects were deﬁned as persons aged >40y who,
between 1995 and 2000, had at least 2 visits to a physi-
cian or one hospital admission with a diagnosis of COPD
and at least 90 days exposure to LABA and/or ICS. Cat-
egories of costs captured included medications, physician
visits, and hospitalizations. Survival was estimated using
a parametric regression model. Costs were adjusted for
censoring and known prognostic factors, including demo-
graphic variables and measures of disease severity. A cost-
effectiveness analysis was conducted from a third party
payer perspective over a time horizon of 36 months.
RESULTS: The estimated average survival and costs
were: 2.4 life years (LY) (CI: 2.3; 2.5) and $43,900 (95%
CI: $38,600; $51,800) for not receiving ICS or LABA; 2.7
LY (CI: 2.6; 2.8) and $36,750 (CI: $29,370; $43,800) 
for ICS alone; 2.7 LY (CI: 2.6; 2.8) and $44,900 (CI:
$38,700; $51,840) for LABA alone; and, 2.8 LY (CI: 2.7;
2.9) and $43,250 (CI: $36,530; $56,900) for subjects
treated with both ICS and LABA. The most favorable
treatment options were ICS and the combination ICS +
LABA. CONCLUSIONS: There is an acute need to ﬁnd
cost-effective treatments for persons with COPD. ICS and
LABA are currently being tested in randomized trials. 
If the impact on survival compares to that shown in
observational studies, those therapies are likely to be cost-
effective in the United States.
RESPIRATORY DISEASES/DISORDERS—Quality of
Life/Preference Based Outcomes
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ASSESSMENT OF THE IMPROVEMENTS IN
QUALITY OF LIFE POST-LUNG TRANSPLANT:
A COMPARISON OF RECIPIENTS VERSUS
CANDIDATES
Matthees BJ1, Lobo FS2, Gross CR2
1Minnesota State University, Moorhead, MN, USA; 2University
of Minnesota, Minneapolis, MN, USA
OBJECTIVES: Lung transplant is increasingly becoming
the choice of therapy for several end-stage pulmonary
conditions. Factors critical to making decisions for a lung
transplant revolve around transplant costs and improve-
ments in health-related quality of life (HRQL) post-
transplant. The primary objectives of this study are: a) 
To compare the HRQL of transplant recipients versus
candidates; and b) To compare recipients versus candi-
dates on utilities derived using two methodologies by
Nichol et al. (2001) and Brazier et al. (2002).
METHODS: A survey questionnaire was mailed to 145
lung or heart-lung transplant recipients and 99 candidates
awaiting lung transplant at a major University hospital in
the Midwestern USA. The questionnaire comprised of
instruments such as the SF-36, Center for Epidemiologic
Studies Depression (CES-D) Scale, Symptom Distress
Scale (SDS), Illness Intrusion Rating Scale (IIRS), Pul-
monary Scale (PS), Dyspnea Scale (DS), and Health Status
(VAS). T-tests were employed to analyze differences
between the two groups on the HRQL measures.
RESULTS: There were a total of 166 respondents (99
recipients and 67 candidates). Recipients had signiﬁcantly
higher SF-36 PCS scores (39.97 vs. 25.56, p = 0.001) and
VAS scores (73.30 vs. 49.24, p = 0.001) as compared to
the candidates. No signiﬁcant differences were observed
between the 2 groups on the SF-36 MCS and CES-D
scores. Recipients demonstrated signiﬁcantly lower levels
of dyspnea, pulmonary distress, and illness intrusion in
comparison to transplant candidates. Both the method-
ologies for deriving utilities from the SF-36 yielded higher
scores for recipients versus the candidates; Nichol utili-
ties (0.76 vs. 0.69, p = 0.001) and Brazier utilities (0.70
vs. 0.63, p = 0.001). CONCLUSIONS: It was observed
that in general recipients had signiﬁcant improvements in
physical health as compared to candidates. The incre-
mental beneﬁt in terms of utilities would be larger when
calculated using the Nichol methodology, despite both
methodologies being based on the SF-36 and standard
gamble. Further research needs focus on the validity of
these utilities for purposes of a cost-utility analysis.
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CULTURAL ADAPTATION AND VALIDATION OF
CHILDHOOD ASTHMA QUESTIONNAIRE-C
(CAQ-C) IN SINGAPORE
Chong LY1, Chay OM2, Goh A2, Seng YC2, Li SC1
1National University of Singapore, Department of Pharmacy,
Singapore, Republic of Singapore; 2KK Women’s and
Children’s Hospital, Singapore, Republic of Singapore
HRQoL is an important outcome measure for chronic
childhood diseases. However, it is infrequently used in
Asia due to the difﬁculty of obtaining appropriately trans-
lated and culturally adapted instruments. We adapted the
Childhood Asthma Questionnaires C (CAQ-C) previ-
ously used in UK and Australia in children aged 11 to 16
years old. OBJECTIVES: To culturally adapt and validate
a disease speciﬁc HRQoL questionnaire, CAQ-C for
childhood asthma in Singapore. METHODS: CAQ-C
was adapted after pre-testing in asthmatic children.
Changes to the UK and Australia versions were made to
reﬂect the Singapore educational system, culture, lan-
guage and climate. A cross-sectional validation was con-
ducted. All consenting asthmatic patients aged 11 years
and above attending the Specialist Respiratory Clinic in
KK Women’s and Children’s Hospital participated.
Patients with other co-morbidities that could signiﬁcantly
affect their HRQoL were excluded. RESULTS: The
adapted CAQ-C was validated in 99 patients (41 females
and 58 males) with a mean age of 12.84 °Ó1.64 years
(range: 10–17 years). More than three quarters completed
the questionnaire in 10 minutes or less. The Severity (12
items), Distress (11 items) and Active Quality of Living
(4 items) scales had similar internal consistency as the UK
and Australian versions (Cronbach’s a = 0.71–0.85). Our
Teenage Quality of Living scale had only 3 items but
